Login to Your Account



ABC key in Celgene DLBCL PFS hit, OS miss; outlook ROBUST

By Randy Osborne
Staff Writer

Tuesday, July 26, 2016

As Celgene Corp. made ready to unveil second-quarter earnings Thursday, onlookers were disappointed but not hugely surprised by the firm's disclosure that it would not seek approval in DLBCL with Revlimid (lenalidomide).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription